Related Experiment Video

Updated: May 27, 2026

Demystifying In Vivo Bioluminescence Imaging of a Chagas Disease Mouse Model for Drug Efficacy Studies
07:59

Demystifying In Vivo Bioluminescence Imaging of a Chagas Disease Mouse Model for Drug Efficacy Studies

Published on: May 31, 2024

Melatonin in Chagas' disease. Possible therapeutic value

Daniel P Cardinali1, Carlos B Alvarez

  • 1Pontificia Universidad Católica Argentina, Buenos Aires. danielcardinali@uca.edu.ar

Medicina
|November 8, 2011
PubMed

Insights

This study explores a novel treatment for Chagas disease, a parasitic infection affecting millions. Combining melatonin and a melatonin agonist may reduce parasite load and prevent heart damage in chronic cases.

Area of Science:

  • Tropical medicine
  • Immunology
  • Pharmacology

Background:

  • Chagas disease, caused by Trypanosoma cruzi, is a major health issue in Latin America, leading to significant mortality and morbidity.
  • Chronic Chagas disease affects 25-30% of infected individuals, often resulting in severe cardiac complications.
  • Effective control of T. cruzi infection requires a robust immune response, including nitric oxide (NO) production by macrophages.

Purpose of the Study:

  • To investigate a potential novel add-on treatment strategy for Chagas disease.
  • To explore the combined therapeutic effects of melatonin and a melatonin agonist (ramelteon) in managing T. cruzi infection.
  • To assess the potential of this combination therapy to reduce parasitemia and mitigate chronic disease progression, particularly cardiomyopathy.

Main Methods:

  • The study hypothesizes a coordinated administration approach.
  • Utilizing a melatonin agonist (ramelteon) during the acute phase to potentially manage parasitemia without affecting NO production.
  • Administering melatonin during the chronic phase to combat oxidative stress and preserve mitochondrial function, thereby preventing cardiomyopathy.

Main Results:

  • Melatonin's role in T. cruzi infection is complex, potentially promoting infection but also reducing parasitemia and NO production at high doses during the acute phase.
  • Sustained oxidative stress and myocardial damage characterize the chronic phase of Chagas disease.
  • The proposed combination therapy aims to leverage the distinct properties of ramelteon and melatonin for synergistic therapeutic benefits.

Conclusions:

  • A coordinated administration of ramelteon and melatonin presents a novel therapeutic hypothesis for Chagas disease.
  • This strategy could potentially address both the acute parasitic load and the chronic cardiac sequelae.
  • Further research is warranted to validate this combination therapy as an effective add-on treatment for Chagas disease.

More Related Videos

In Vitro Drug Screening Against All Life Cycle Stages of Trypanosoma cruzi Using Parasites Expressing β-galactosidase08:48

In Vitro Drug Screening Against All Life Cycle Stages of Trypanosoma cruzi Using Parasites Expressing β-galactosidase

Published on: November 5, 2021

High-Throughput Small Molecule Drug Screening For Age-Related Sleep Disorders Using Drosophila melanogaster05:59

High-Throughput Small Molecule Drug Screening For Age-Related Sleep Disorders Using Drosophila melanogaster

Published on: October 20, 2023

Related Concept Videos

Management of Insomnia01:19

Management of Insomnia

The sleep cycle, an integral part of human health, consists of several stages with distinct characteristics and functions. It begins with a transition from wakefulness to sleep, known as the light sleep phase, followed by the restorative deep sleep phase, essential for physical recovery and growth. The cycle concludes with the Rapid Eye Movement (REM) phase, characterized by high brain activity and vivid dreaming. Insomnia, a prevalent sleep disorder, involves difficulty falling asleep, staying...
American Trypanosomiasis01:22

American Trypanosomiasis

Chagas disease, or American trypanosomiasis, is a vector-borne parasitic infection caused by Trypanosoma cruzi, a flagellated protozoan (kinetoplastid) of the family Trypanosomatidae. The disease is endemic in Latin America, although cases are increasingly reported worldwide due to human migration. Transmission most commonly occurs when feces of infected triatomine bugs contaminate bite wounds or mucosal surfaces; additional routes include congenital, transfusional, transplant-related, and oral...
Sedatives and Hypnotics Drugs: Miscellaneous Agents01:17

Sedatives and Hypnotics Drugs: Miscellaneous Agents

Sedatives and hypnotics encompass a wide range of substances, each with its unique mechanism of action, uses, and potential adverse effects.
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...
Antiprotozoal Agents01:21

Antiprotozoal Agents

Leishmaniasis is a widespread parasitic disease caused by several Leishmania species. It affects millions of people each year and remains a major public health problem in endemic regions. First-line treatment relies on pentavalent antimonials, including meglumine antimoniate and sodium stibogluconate. Even so, how these drugs work has not been fully clear, especially their interaction with parasite-specific biochemical pathways. One key target is trypanothione reductase (TR), an enzyme that...
Cholinergic Antagonists: Therapeutic Uses01:26

Cholinergic Antagonists: Therapeutic Uses

Antimuscarinic drugs have various therapeutic applications by inhibiting parasympathetic stimulation in different systems. Here are the key therapeutic uses of antimuscarinics:    
Respiratory Tract: Ipratropium, aclidinium, and tiotropium treat asthma, chronic bronchitis, and chronic obstructive pulmonary disease (COPD). They protect against bronchoconstriction caused by irritants like cigarette smoke, sulfur dioxide, and ozone. They also help reduce nasopharyngeal secretions in common...
Esophageal Achalasia01:27

Esophageal Achalasia

Esophageal achalasia is a chronic neurogenic disorder characterized by impaired relaxation of the lower esophageal sphincter (LES) and absent or ineffective peristalsis in the distal esophagus. This leads to a functional obstruction without a physical blockage, despite significant disruption of esophageal motility.EtiologyAchalasia is caused by degeneration of the myenteric (Auerbach's) plexus, specifically the loss of inhibitory ganglion cells that produce vasoactive intestinal peptide (VIP)...